Pharmacokinetics of antifungal agents in children

Early Human Development

Volumn 87, Issue SUPPL., 2011, Pages

  Watt, Kevin ^a   Benjamin, Daniel K ^a,b   Cohen Wolkowiez, Michael ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antifungal agents; Children; Infants; Neonates; Pharmacokinetics; Pharmacology

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS; BONE MARROW SUPPRESSION; CANDIDA; CANDIDA MENINGITIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; HUMAN; LIVER INJURY; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYCOSIS; NEPHROTOXICITY; NONHUMAN; PEDIATRICS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREMATURITY; RECOMMENDED DRUG DOSE;

ADULT; ANTIFUNGAL AGENTS; CHILD; ECHINOCANDINS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; NUCLEOSIDES; POLYENES; PREVENTIVE MEDICINE; TRIAZOLES;

EID: 79951812665     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2011.01.014     Document Type: Article

References (84)

1. Boschman C.R., Bodnar U.R., Tornatore M.A., Obias A.A., Noskin G.A., Englund K., et al. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother Apr 1998, 42(4):734-738.
2. Magill S.S., Swoboda S.M., Shields C.E., Colantuoni E.A., Fothergill A.W., Merz W.G., et al. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. Ann Surg Apr 2009, 249(4):657-665.
3. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med Jun 1996, 100(6):617-623.
4. Krause D.S., Simjee A.E., van Rensburg C., Viljoen J., Walsh T.J., Goldstein B.P., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis Sep 15 2004, 39(6):770-775.
5. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet Oct 22-28 2005, 366(9495):1435-1442.
6. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med Dec 19 2002, 347(25):2020-2029.
7. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med Jun 14 2007, 356(24):2472-2482.
8. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., van der Horst C.M., Edwards J.E., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med Nov 17 1994, 331(20):1325-1330.
9. Rex J.H., Pappas P.G., Karchmer A.W., Sobel J., Edwards J.E., Hadley S., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis May 15 2003, 36(10):1221-1228.
10. Emminger W., Lang H.R., Emminger-Schmidmeier W., Peters C., Gadner H. Amphotericin B serum levels in pediatric bone marrow transplant recipients. Bone Marrow Transplant Feb 1991, 7(2):95-99.
11. Baley J.E., Meyers C., Kliegman R.M., Jacobs M.R., Blumer J.L. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr May 1990, 116(5):791-797.
12. Benson J.M., Nahata M.C. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother Nov 1989, 33(11):1989-1993.
13. Koren G., Lau A., Klein J., Golas C., Bologa-Campeanu M., Soldin S., et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr Sep 1988, 113(3):559-563.
14. Starke J.R., Mason E.O., Kramer W.G., Kaplan S.L. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis Apr 1987, 155(4):766-774.
15. Nath C.E., McLachlan A.J., Shaw P.J., Gunning R., Earl J.W. Population pharmacokinetics of amphotericin B in children with malignant diseases. Br J Clin Pharmacol Dec 2001, 52(6):671-680.
16. Luna B., Drew R.H., Perfect J.R. Agents for treatment of invasive fungal infections. Otolaryngol Clin North Am 2000, 33:277-299.
17. Ralph E.D., Khazindar A.M., Barber K.R., Grant C.W.M. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob Agents Chemother 1991, 35:188-191.
18. Wurthwein G., Groll A.H., Hempel G., Adler-Shohet F.C., Lieberman J.M., Walsh T.J. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother Dec 2005, 49(12):5092-5098.
19. Hong Y., Shaw P.J., Nath C.E., Yadav S.P., Stephen K.R., Earl J.W., et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother Mar 2006, 50(3):935-942.
20. Kotwani R.N., Gokhale P.C., Bodhe P.V., Kirodian B.G., Kshirsagar N.A., Pandya S.K. A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates. Int J Pharm May 15 2002, 238(1-2):11-15.
21. Walsh T.J., Goodman J.L., Pappas P., Bekersky I., Buell D.N., Roden M., et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerate dose study. Antimicrob Agents Chemother 2001, 45:3487-3496.
22. Bennet J.E. Flucytosine. Ann Intern Med Mar 1977, 86(3):319-321.
23. Mauceri A.A., Cullen S.I., Vandevelde A.G., Johnson J.E. Flucytosine. An effective oral treatment for chromomycosis. Arch Dermatol Jun 1974, 109(6):873-876.
24. Denning D.W., Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2, 121 published cases. Rev Infect Dis 1990, 12:1147-1200.
25. Song J.C., Deresinski S. Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs Feb 2005, 6(2):170-177.
26. Stamm A.M., Diasio R.B., Dismukes W.E., Shadomy S., Cloud G.A., Bowles C.A., et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med Aug 1987, 83(2):236-242.
27. Benson J.M., Nahata M.C. Clinical use of systemic antifungal agents. Clin Pharm Jun 1988, 7(6):424-438.
28. Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc Dec 1998, 73(12):1205-1225.
29. Benjamin D.K.J., Stoll B.J., Fanaroff A.A., McDonald S.A., Oh W., R D, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006, 117:84-92.
30. Anaissie E.J., Darouiche R.O., Abi-Said D., Uzun O., Mera J., Gentry L.O., et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis Nov 1996, 23(5):964-972.
31. Phillips J.R., Karlowicz M.G. Prevalence of Candida species in hospital-acquired urinary tract infections in a neonatal intensive care unit. Pediatr Infect Dis J Feb 1997, 16(2):190-194.
32. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet Jul 1997, 33(1):52-77.
33. Wildfeuer A., Laufen H., Schmalreck A.F., Yeates R.A., Zimmermann T. Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses Nov 1997, 40(7-8):259-265.
34. Brammer K.W., Coates P.E. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis Apr 1994, 13(4):325-329.
35. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997, 33:52-77.
36. Wade K.C., Wu D., Kaufman D.A., Ward R.M., Benjamin D.K., Sullivan J.E., et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother Nov 2008, 52(11):4043-4049.
37. Piper L.S.P., Hornik C.P., Cheifetz I.M., Barrett J., Hope W., Moorthy G., et al. Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. Society for Pediatric Research Conference, Vancouver, Canada, May 2010 2010, [Abstract].
38. Sabo J.A., Abdel-Rahman S.M. Voriconazole: a new triazole antifungal. Ann Pharmacother 2000, 34:1032-1043.
39. Manavathu E.K., Cutright J.L., Chandrasekar P.H. In vitro susceptibility of itraconazole-resistant isolates of Aspergillus fumigatus to voriconazole. Clin Microbiol Infect 1997, 3(Suppl 2):81.
40. Johnson E.M., Szekely A., Warnock D.W. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998, 42:741-745.
41. Purkins L., Wood N., Ghahramani P., Greenhalgh K., Allen M.J., Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother Aug 2002, 46(8):2546-2553.
42. Purkins L., Wood N., Greenhalgh K., Allen M.J., Oliver S.D. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol Dec 2003, 56(Suppl 1):10-16.
43. UK-109496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man [abstract F78] 1995, American Society for Microbiology, Washington, DC. B. Patterson (Ed.).
44. Myrianthefs P., Markantonis S.L., Evaggelopoulou P., Despotelis S., Evodia E., Panidis D., et al. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Int J Antimicrob Agents May 2010, 42(5):468-472.
45. Lazarus H.M., Blumer J.L., Yanovich S., Schlamm H., Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol Apr 2002, 42(4):395-402.
46. Hyland R., Jones B.C., Smith D.A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos May 2003, 31(5):540-547.
47. Ikeda Y., Umemura K., Kondo K., Sekiguchi K., Miyoshi S., Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther Jun 2004, 75(6):587-588.
48. Walsh T.J., Karlsson M.O., Driscoll T., Arguedas A.G., Adamson P., Saez-Llorens X., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother Jun 2004, 48(6):2166-2172.
49. Karlsson M.O., Lutsar I., Milligan P.A. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother Mar 2009, 53(3):935-944.
50. Boyd A.E., Modi S., Howard S.J., Moore C.B., Keevil B.G., Denning D.W. Adverse reactions to voriconazole. Clin Infect Dis Oct 15 2004, 39(8):1241-1244.
51. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis Mar 1 2002, 34(5):563-571.
52. Imhof A., Schaer D.J., Schanz U., Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly Nov 11 2006, 136(45-46):739-742.
53. Smith J., Safdar N., Knasinski V., Simmons W., Bhavnani S.M., Ambrose P.G., et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother Apr 2006, 50(4):1570-1572.
54. Trifilio S., Pennick G., Pi J., Zook J., Golf M., Kaniecki K., et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer Apr 15 2007, 109(8):1532-1535.
55. Pasqualotto A.C., Shah M., Wynn R., Denning D.W. Voriconazole plasma monitoring. Arch Dis Child Jul 2008, 93(7):578-581.
56. Neely M., Rushing T., Kovacs A., Jelliffe R., Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis Jan 1 2010, 50(1):27-36.
57. Muldrew K.M., Maples H.D., Stowe C.D., Jacobs R.F. Intravenous voriconazole therapy in a preterm infant. Pharmacotherapy Jun 2005, 25(6):893-898.
58. Santos R.P., Sanchez P.J., Mejias A., Benjamin D.K., Walsh T.J., Patel S., et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J Apr 2007, 26(4):364-366.
59. Maples H.D., Stowe C.D., Saccente S.L., Jacobs R.F. Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection. Pediatr Infect Dis J Nov 2003, 22(11):1022-1024.
60. Courtney R., Pai S., Laughlin M., Lim J., Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother Sep 2003, 47(9):2788-2795.
61. Groll A.H., Mickiene D., Petraitis V., Petraitiene R., Ibrahim K.H., Piscitelli S.C., et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother Dec 2001, 45(12):3322-3327.
62. Moore C.B., Walls C.M., Denning D.W. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000, 44:441-443.
63. Arikan S., Rex J.H. Ravuconazole. Curr Opin Investig Drugs 2002, 3:555-561.
64. Ravuconazole single ascending oral dose study in healthy subjects 2000, Toronto, Ontario: Washington, DC. S.J. Olsen, V. Mummaneni, P. Rolan, J. Norton, D.M. Grasela (Eds.).
65. Mikamo H., Yin X.H., Hayasaki Y., Shimamura Y., Uesugi K., Fukayama N., et al. Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Chemotherapy 2002, 48:7-9.
66. Faix R.G., Polley T.Z., Grasela T.H. A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis. J Pediatr Feb 1988, 112(2):271-277.
67. Ernst E.J. Investigational antifungal agents. Pharmacotherapy Aug 2001, 21(8 Pt 2):165S-174S.
68. Walsh T.J., Viviani M.A., Arathoon E., Chiou C., Ghannoum M., Groll A.H., et al. New targets and delivery systems for antifungal therapy. Med Mycol 2000, 38(Suppl 1):335-347.
69. Groll A.H., Piscitelli S.C., Walsh T.J. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy Aug 2001, 21(8 Pt 2):133S-148S.
70. Merck. Caspofungin Product Label. In: Administration FaD, editor.2010.
71. Lipp H.P. Antifungal agents-clinical pharmacokinetics and drug interactions. Mycoses 2008, 51(Suppl 1):7-18.
72. Neely M., Jafri H.S., Seibel N., Knapp K., Adamson P.C., Bradshaw S.K., et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother Apr 2009, 53(4):1450-1456.
73. Saez-Llorens X., Macias M., Maiya P., Pineros J., Jafri H.S., Chatterjee A., et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3months of age. Antimicrob Agents Chemother Mar 2009, 53(3):869-875.
74. Seibel N.L., Schwartz C., Arrieta A., Flynn P., Shad A., Albano E., et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother Aug 2005, 49(8):3317-3324.
75. Tabata K., Katashima M., Kawamura A., Tanigawara Y., Sunagawa K. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull Aug 2006, 29(8):1706-1711.
76. Hope W.W., Mickiene D., Petraitis V., Petraitiene R., Kelaher A.M., Hughes J.E., et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis Jan 1 2008, 197(1):163-171.
77. Heresi G.P., Gerstmann D.R., Reed M.D., van den Anker J.N., Blumer J.L., Kovanda L., et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J Dec 2006, 25(12):1110-1115.
78. Smith P.B., Walsh T.J., Hope W., Arrieta A., Takada A., Kovanda L.L., et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J May 2009, 28(5):412-415.
79. Sirohi B., Powles R.L., Chopra R., Russell N., Byrne J.L., Prentice H.G., et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant Jul 2006, 38(1):47-51.
80. Damle B., Stogniew M., Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother Jul 2008, 52(7):2673-2676.
81. Dowell J.A., Knebel W., Ludden T., Stogniew M., Krause D., Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol Jun 2004, 44(6):590-598.
82. Estes K.E., Penzak S.R., Calis K.A., Walsh T.J. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy Jan 2009, 29(1):17-30.
83. Benjamin D.K., Driscoll T., Seibel N.L., Gonzalez C.E., Roden M.M., Kilaru R., et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother Feb 2006, 50(2):632-638.
84. Abstract: Safety and Pharmacokinetics (PK) of Multiple-Dose Anidulafungin in Neonates 2010, Boston, MA. M. Cohen-Wolkowiez, D.K. Benjamin, L. Piper, C. Moran, P. Liu, J. Aram (Eds.).